Teva Pharmaceutical is weighing options for its active pharmaceutical ingredients, or API, business, including a possible sale, people with knowledge of the matter told Bloomberg’s Dinesh Nair. The company is working with advisers as it seeks to gauge interest in the Teva API unit from potential buyers, according to the sources, who said deal could value the business at about $2B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TEVA:
- Teva announces data from PEARL study on AJOVY in migraine prevention
- Teva call volume above normal and directionally bullish
- Unusually active option classes on open June 29th
- Teva settles with Kentucky on pricing fixing claims
- Alvotech & Teva secure AVT04 license date, for proposed Stelara biosimilar